A Phase 2 interventional study of RPL554 and Placebo in Cystic Fibrosis, sponsored by Verona Pharma plc. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-21.
Sponsored by Verona Pharma plc (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Cystic Fibrosis by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Cystic Fibrosis · Merck & Co., Inc.
Among the 10 studies in Cystic Fibrosis by Merck & Co., Inc, this one is the 9th largest by enrollment, is the only one that started in 2017, is one of 6 in phase 2, and was the 10th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 200 are open to participants now.
Browse Cystic Fibrosis studies →None of the 10 studies in Cystic Fibrosis by Merck & Co., Inc is open now. The open studies under Cystic Fibrosis, anywhere →
Of the 155 Cystic Fibrosis studies recruiting now, 94 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 3
First in 2001; this study’s year is marked. 1 started in 2017.
This study's enrollment of 10 is below the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 68 across the 10 interventional studies. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Verona Pharma plc, one of the names counted as Merck & Co., Inc. Under that name alone:
Verona Pharma plc is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Cystic Fibrosis by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates two doses of RPL554 and placebo in adult patients with cystic fibrosis. All patients receive all three treatments in a randomised sequence.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Sign an document indicating they understand the purpose of and procedures required for the study and are willing to participate in the study.
No abnormality including morphology (e.g. left bundle branch block, atrioventricular nodal dysfunction, ST segment abnormalities) 4. Capable of complying with all study restrictions and procedures including ability to use the study nebuliser correctly.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose of inhaled 6 mg RPL554
Drug: RPL554
Single dose of inhaled 1.5 mg RPL554
Drug: RPL554
Inhaled placebo dose
Drug: Placebo
RPL554 suspension administered using a nebuliser
Placebo solution administered using a nebuliser
AUC by Dose
Area under the curve (AUC)
Time frame: Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose after each treatment
Maximum Plasma Concentration After Each Dose
Maximum plasma concentration (Cmax) after a single dose of RPL554
Time frame: Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose
Time to Maximum Plasma Concentration After Each Dose
Time to maximum concentration (Tmax) after a single dose of RPL554
Time frame: Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose
Half Life for Each Dose
Half life (t1/2) of RPL554
Time frame: Pre dose, 15 and 30 minutes and 1, 2, 4, 6, 8 and 24 hours post dose
Peak FEV1 for Each Treatment
Maximum Forced expired volume in one second (FEV1) measured using spirometry
Time frame: Pre dose and 15 and 30 minutes and 1, 2 and 4 hours post dose after treatment
AUC FEV1(0-4h)
Area under the curve for FEV1 over 4 hours measured using spirometry
Time frame: Pre dose and 15 and 30 minutes and 1, 2 and 4 hours post dose
AUC FEV1(0-6h)
Area under the curve FEV1 over 6 hours measured using spirometry
Time frame: Pre dose and 15 and 30 minutes and 1, 2, 4 and 6 hours post dose
AUC FEV1(0-8h)
Area under the curve for FEV1 over 8 hours measured using spirometry
Time frame: pre dose and 15 and 30 minutes and 1, 2, 4, 6 and 8 hours post dose
FVC
Forced vital capacity (FVC) measured using spirometry
Time frame: Over 24 hours after treatment
Breath Samples
Exhaled breath pH
Time frame: 8 and 24 hours after treatment
Laboratory Safety Tests 1
Biochemistry panel parameters
Time frame: Screening and end of study
Laboratory Safety Tests 2
Haematology panel parameters
Time frame: Screening and end of study
Laboratory Safety Tests 3
Urinalysis measured by urine dipstick
Time frame: Screening and end of study
Vital Signs 1
Pulse rate after 5 minutes supine
Time frame: Over 8 hours after treatment
Vital Signs 2
Blood pressure after 5 minutes supine
Time frame: Over 8 hours after treatment
ECG 1
Heart rate
Time frame: Over 8 hours after treatment
ECG 2
QT interval
Time frame: Over 8 hours after treatment
Sputum Rheology
Rheological analysis for interleukin 8, tumour necrosis factor alpha and myeloperoxidase
Time frame: 8 and 12 hours after treatment
Sputum Measurements
Levels of inflammatory mediators
Time frame: 8 and 12 hours after treatment
| Milestone | Higher Dose RPL554/Lower Dose RPL554/Placebo | Lower Dose RPL554/Placebo/Higher Dose RPL554 | Higher Dose RPL554/Plaebo/Lower Dose RPL554 | Lower Dose RPL554/Higher Dose RPL554/Placebo | Placebo/Higher Dose RPL554/Lower Dose RPL554 | Placebo/Lower Dose RPL554/Higher Dose RPL554 |
|---|---|---|---|---|---|---|
| Started | 1 | 2 | 2 | 2 | 1 | 2 |
| Completed | 1 | 2 | 2 | 2 | 1 | 1 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 |
Area under the curve (AUC)
| pg*h/mL | Higher Dose RPL554 | Lower Dose RPL554 |
|---|---|---|
| AUC by Dose | 7699 ± 2965.7 | 2342 ± 1029.9 |
Maximum plasma concentration (Cmax) after a single dose of RPL554
| pg/mL | Higher Dose RPL554 | Lower Dose RPL554 |
|---|---|---|
| Maximum Plasma Concentration After Each Dose | 828.3 ± 256.1 | 270.1 ± 91.9 |
Time to maximum concentration (Tmax) after a single dose of RPL554
| hours | Higher Dose RPL554 | Lower Dose RPL554 |
|---|---|---|
| Time to Maximum Plasma Concentration After Each Dose | 1.53 ± 0.66 | 1.33 ± 0.62 |
Half life (t1/2) of RPL554
| Hours | Higher Dose RPL554 | Lower Dose RPL554 |
|---|---|---|
| Half Life for Each Dose | 10.14 ± 3.1 | 7.52 ± 3.3 |
Maximum Forced expired volume in one second (FEV1) measured using spirometry
| Liters | Higher Dose RPL554 | Lower Dose RPL554 | Placebo |
|---|---|---|---|
| Peak FEV1 for Each Treatment | 2.384 ± 0.73 | 2.247 ± 0.72 | 2.256 ± 0.71 |
Area under the curve for FEV1 over 4 hours measured using spirometry
| Liters | Higher Dose RPL554 | Lower Dose RPL554 | Placebo |
|---|---|---|---|
| AUC FEV1(0-4h) | 2.313 ± 0.73 | 2.194 ± 0.72 | 2.133 ± 0.73 |
Area under the curve FEV1 over 6 hours measured using spirometry
| Liters | Higher Dose RPL554 | Lower Dose RPL554 | Placebo |
|---|---|---|---|
| AUC FEV1(0-6h) | 2.304 ± 0.74 | 2.188 ± 0.73 | 2.133 ± 0.73 |
Area under the curve for FEV1 over 8 hours measured using spirometry
| Liters | Higher Dose RPL554 | Lower Dose RPL554 | Placebo |
|---|---|---|---|
| AUC FEV1(0-8h) | 2.287 ± 0.75 | 2.185 ± 0.74 | 2.130 ± 0.74 |
Forced vital capacity (FVC) measured using spirometry
Results for this outcome have not been posted.
Exhaled breath pH
Results for this outcome have not been posted.
Biochemistry panel parameters
Results for this outcome have not been posted.
Haematology panel parameters
Results for this outcome have not been posted.
Urinalysis measured by urine dipstick
Results for this outcome have not been posted.
Pulse rate after 5 minutes supine
Results for this outcome have not been posted.
Blood pressure after 5 minutes supine
Results for this outcome have not been posted.
Heart rate
Results for this outcome have not been posted.
QT interval
Results for this outcome have not been posted.
Rheological analysis for interleukin 8, tumour necrosis factor alpha and myeloperoxidase
Results for this outcome have not been posted.
Levels of inflammatory mediators
Results for this outcome have not been posted.
Collected over From informed consent through study completion, up to 52 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Higher Dose RPL554 | 0/9 (0%) | 0/9 (0%) | 6/9 (66.7%) |
| Lower Dose RPL554 | 0/10 (0%) | 1/10 (10%) | 6/10 (60%) |
| Placebo | 0/10 (0%) | 0/10 (0%) | 3/10 (30%) |
| Event | Higher Dose RPL554 | Lower Dose RPL554 | Placebo |
|---|---|---|---|
| exacerbation of cystic fibrosisInfections and infestations | 0/9 | 1/10 | 0/10 |
| Event | Higher Dose RPL554 | Lower Dose RPL554 | Placebo |
|---|---|---|---|
| TachycardiaCardiac disorders | 2/9 | 2/10 | 1/10 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/9 | 1/10 | 0/10 |
| Forced expiratory volume decreasedInvestigations | 1/9 | 0/10 | 0/10 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 1/9 | 0/10 | 0/10 |
| Chest discomfortGeneral disorders | 1/9 | 1/10 | 0/10 |
| NauseaGastrointestinal disorders | 1/9 | 0/10 | 0/10 |
| Oral candidiasisInfections and infestations | 1/9 | 0/10 | 0/10 |
| Pulmonary function test decreasedInvestigations | 0/9 | 1/10 | 1/10 |
| Drug hypersensitivityImmune system disorders | 0/9 | 1/10 | 0/10 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/9 | 0/10 | 1/10 |
| Age, Categorical(Participants) | Higher Dose RPL554/Lower Dose RPL554/Placebo | Lower Dose RPL554/Placebo/Higher Dose RPL554 | Higher Dose RPL554/Placebo/Lower Dose RPL554 | Lower Dose RPL554/Higher Dose RPL554/Placebo | Placebo/Higher Dose RPL554/Lower Dose RPL554 | Placebo/Lower Dose RPL554/Higher Dose RPL554 | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 2 | 2 | 2 | 1 | 2 | 10 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Higher Dose RPL554/Lower Dose RPL554/Placebo | Lower Dose RPL554/Placebo/Higher Dose RPL554 | Higher Dose RPL554/Placebo/Lower Dose RPL554 | Lower Dose RPL554/Higher Dose RPL554/Placebo | Placebo/Higher Dose RPL554/Lower Dose RPL554 | Placebo/Lower Dose RPL554/Higher Dose RPL554 | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 2 | 1 | 0 | 1 | 4 |
| Male | 1 | 2 | 0 | 1 | 1 | 1 | 6 |
| Race (NIH/OMB)(Participants) | Higher Dose RPL554/Lower Dose RPL554/Placebo | Lower Dose RPL554/Placebo/Higher Dose RPL554 | Higher Dose RPL554/Placebo/Lower Dose RPL554 | Lower Dose RPL554/Higher Dose RPL554/Placebo | Placebo/Higher Dose RPL554/Lower Dose RPL554 | Placebo/Lower Dose RPL554/Higher Dose RPL554 | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 1 | 2 | 2 | 2 | 1 | 2 | 10 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2017 to primary completion in Nov 2017, 8 months.
Results were first posted in Mar 2019, 1 year 4 months after primary completion.
Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 8 months is below that.
Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ensifentrine